Alnylam Pharmaceuticals Trading Volume Surges to $289 Million Ranking 356th in Daily Volume

On July 15, 2025, Alnylam Pharmaceuticals (ALNY) saw a significant increase in trading volume, reaching $289 million, marking a 44.98% rise from the previous day. This surge placed Alnylam among the top 356 stocks by trading volume for the day. However, the stock price closed down 1.47%.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 2026.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the European Medicines Agency (EMA) has accepted for review the company's Marketing Authorization Application (MAA) for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). The EMA has set a target date for a decision of March 2026.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the company has entered into a collaboration agreement with a leading biopharmaceutical company to develop and commercialize a new RNAi therapeutic for the treatment of a rare genetic disorder. The collaboration will focus on the development of a novel RNAi therapeutic that targets a specific gene involved in the disease.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the company has received a Breakthrough Therapy Designation from the FDA for its investigational RNAi therapeutic, lumasiran, for the treatment of primary hyperoxaluria type 1 (PH1). This designation is based on preliminary clinical data that demonstrate the potential of lumasiran to address a significant unmet medical need in patients with PH1.